No profile data available.
Tectonic Therapeutic, Inc. (TECX) is a healthcare company in the blood vessel treatment pharmaceuticals industry, based in Watertown, United States, with about 60 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$74.15 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0. Its market capitalization was $456.09 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
Tectonic Therapeutic reported $0 in revenue for fiscal year 2025. In Q1 2026 revenue was $0.
$456.09 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood vessel treatment pharmaceuticals) include Mineralys Therapeutics, Inc. (MLYS), Palvella Therapeutics, Inc. (PVLA), Gossamer Bio, Inc. (GOSS), DiaMedica Therapeutics Inc. (DMAC).